Diverse targets of SMN2 -directed splicing-modulating small molecule therapeutics for spinal muscular atrophy
Nucleic Acids Research · 07.07.2023 · 51 (12) · 5948-5980
DOI: 10.1093/nar/gkad259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 07.04.2023. Verfasst von Eric W Ottesen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, USA. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, RNA Splicing. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Designing an RNA-interacting molecule that displays high therapeutic efficacy while retaining specificity within a broad concentration range remains a challenging task. Risdiplam is an FDA-approved small molecule for the treatment of spinal muscular atrophy (SMA), the leading genetic cause of infant mortality. Branaplam is another small molecule which has undergone clinical trials. The therapeutic merit of both compounds is based on their ability to restore body-wide inclusion of Survival Motor Neuron 2 (SMN2) exon 7 upon oral administration. Here we compare the transcriptome-wide off-target effects of these compounds in SMA patient cells. We captured concentration-dependent compound-specific changes, including aberrant expression of genes associated with DNA replication, cell cycle, RNA metabolism, cell signaling and metabolic pathways. Both compounds triggered massive perturbations of splicing events, inducing off-target exon inclusion, exon skipping, intron retention, intron removal and alternative splice site usage. Our results of minigenes expressed in HeLa cells provide mechanistic insights into how these molecules targeted towards a single gene produce different off-target effects. We show the advantages of combined treatments with low doses of risdiplam and branaplam. Our findings are instructive for devising better dosing regimens as well as for developing the next generation of small molecule therapeutics aimed at splicing modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, USA.
ORCID-Profile: Ravindra N Singh
Förderung
- NINDS NIH HHS
- NIH HHS
- National Institutes of Health
- Iowa State University
- NIH
Zitieren
APA
Ottesen, E. W., Singh, N. N., Luo, D., Kaas, B., Gillette, B. J., Seo, J., Jorgensen, H. J., & Singh, R. N. (2023). Diverse targets of SMN2 -directed splicing-modulating small molecule therapeutics for spinal muscular atrophy. Nucleic Acids Research, 51(12), 5948-5980. https://doi.org/10.1093/nar/gkad259
Vancouver
Ottesen EW, Singh NN, Luo D, Kaas B, Gillette BJ, Seo J, et al. Diverse targets of SMN2 -directed splicing-modulating small molecule therapeutics for spinal muscular atrophy. Nucleic Acids Research. 2023;51(12):5948-5980. doi:10.1093/nar/gkad259
BibTeX
@article{Ottesen2023,
author = {Ottesen, Eric W and Singh, Natalia N and Luo, Diou and Kaas, Bailey and Gillette, Benjamin J and Seo, Joonbae and Jorgensen, Hannah J and Singh, Ravindra N},
title = {Diverse targets of SMN2 -directed splicing-modulating small molecule therapeutics for spinal muscular atrophy},
journal = {Nucleic Acids Research},
year = {2023},
volume = {51},
number = {12},
pages = {5948--5980},
doi = {10.1093/nar/gkad259}
}
EUVIMED